Clinical and laboratory features of patients with CLL
. | . | . | . | . | % loss of viability at 5 and 10 μM OSU03012 . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | 24 h . | . | 72 h . | . | |||
| Patient no. . | Rai stage . | ISCN . | Interphase cytogenetics . | No. trts . | 5 μM . | 10 μM . | 5 μM . | 10 μM . | |||
| 1 | Intermediate | 46,XX[14]/nonclonal[6] | del(11)(q22), del(13)(q14.3) | 6 | 77.6 | 35.8 | 76.1 | 11.4 | |||
| 2 | Intermediate | 47,XY, + 12[8]/46,XY[12] | Trisomy 12 | 0 | 89.6 | 30.3 | 79.0 | 15.2 | |||
| 3 | Intermediate | 46,XX,?inv(4)(p1?2q2?3),?14[4]/45,X,-X[3]/46,XX[17] | del(13)(q14.3) | 1 | 70.7 | 39.0 | 24.8 | 11.5 | |||
| 4 | Low | 46,XX[20] | No abnormality | 0 | 76.5 | 27.3 | 75.4 | 15.4 | |||
| 5 | Intermediate | 46,XY,del(6)(q15)[2]/nonclonal[1]/4n[1]/46,XY[15] | No abnormality | 0 | 54.0 | 22.1 | 40.4 | 7.7 | |||
| 6 | Intermediate | NA | No abnormality | 0 | 63.4 | 26.5 | 52.0 | 11.4 | |||
| 7 | Intermediate | 47,XY, + 12[cp3]/45,X,-Y[5]/46,XY[12] | Trisomy 12 | 5 | 35.8 | 13.7 | 17.0 | 7.5 | |||
| 8 | Intermediate | 46,XY,t(3;10)(p21;q24)[4]/46,XY[16]/nonclonal[1] | del(13)(q14.3) | 0 | 88.0 | 22.0 | 74.7 | 12.3 | |||
| 9 | Intermediate | 46,XY[20] | No abnormality | 0 | 93.2 | 39.6 | 85.0 | 17.8 | |||
| 10 | Intermediate | NA | No abnormality | 0 | 89.1 | 34.8 | 79.2 | 11.2 | |||
| 11 | Intermediate | 46,XY[19]/nonclonal[1] | Trisomy 12 | 0 | ND | ND | 50.2 | 29.7 | |||
. | . | . | . | . | % loss of viability at 5 and 10 μM OSU03012 . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | 24 h . | . | 72 h . | . | |||
| Patient no. . | Rai stage . | ISCN . | Interphase cytogenetics . | No. trts . | 5 μM . | 10 μM . | 5 μM . | 10 μM . | |||
| 1 | Intermediate | 46,XX[14]/nonclonal[6] | del(11)(q22), del(13)(q14.3) | 6 | 77.6 | 35.8 | 76.1 | 11.4 | |||
| 2 | Intermediate | 47,XY, + 12[8]/46,XY[12] | Trisomy 12 | 0 | 89.6 | 30.3 | 79.0 | 15.2 | |||
| 3 | Intermediate | 46,XX,?inv(4)(p1?2q2?3),?14[4]/45,X,-X[3]/46,XX[17] | del(13)(q14.3) | 1 | 70.7 | 39.0 | 24.8 | 11.5 | |||
| 4 | Low | 46,XX[20] | No abnormality | 0 | 76.5 | 27.3 | 75.4 | 15.4 | |||
| 5 | Intermediate | 46,XY,del(6)(q15)[2]/nonclonal[1]/4n[1]/46,XY[15] | No abnormality | 0 | 54.0 | 22.1 | 40.4 | 7.7 | |||
| 6 | Intermediate | NA | No abnormality | 0 | 63.4 | 26.5 | 52.0 | 11.4 | |||
| 7 | Intermediate | 47,XY, + 12[cp3]/45,X,-Y[5]/46,XY[12] | Trisomy 12 | 5 | 35.8 | 13.7 | 17.0 | 7.5 | |||
| 8 | Intermediate | 46,XY,t(3;10)(p21;q24)[4]/46,XY[16]/nonclonal[1] | del(13)(q14.3) | 0 | 88.0 | 22.0 | 74.7 | 12.3 | |||
| 9 | Intermediate | 46,XY[20] | No abnormality | 0 | 93.2 | 39.6 | 85.0 | 17.8 | |||
| 10 | Intermediate | NA | No abnormality | 0 | 89.1 | 34.8 | 79.2 | 11.2 | |||
| 11 | Intermediate | 46,XY[19]/nonclonal[1] | Trisomy 12 | 0 | ND | ND | 50.2 | 29.7 | |||
Written, informed consent was obtained to procure cells from patients with previously diagnosed CLL as defined by the modified NCI criteria. All of the patients with CLL had been without prior therapy for a minimum of 2 months. % Loss of viability was measured by MTT assay.
ISCN indicates International System for Human Cytogenetic Nomenclature; trts, previous therapies.